I think there's a good chance we garner the first UP deal. Who ever the suitor is maybe Novartis or who ever it may be has put themselves in line for multiple bites at the bigger apple for the more extensive forms of Inflammatory Bowel Disease as written in the May16 pr. We just have to wait and see. Also the way I see it for the suitor to get more bites they have to first sign a deal.

"The non-binding term sheet also includes a Right of First Refusal for rights to Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications".